1. Pleiotropic effects of statins via interaction with the lipid bilayer: A combined approach.
- Author
-
Penkauskas T, Zentelyte A, Ganpule S, Valincius G, and Preta G
- Subjects
- Anticholesteremic Agents chemistry, Anticholesteremic Agents pharmacology, Cardiovascular Diseases etiology, Cell Membrane drug effects, Cell Membrane metabolism, Cholesterol metabolism, Humans, Hydrophobic and Hydrophilic Interactions, Hydroxymethylglutaryl-CoA Reductase Inhibitors chemistry, Hypercholesterolemia complications, Lipid Bilayers chemistry, Cardiovascular Diseases drug therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Hypercholesterolemia drug therapy, Lipid Bilayers antagonists & inhibitors
- Abstract
Statins are effective inhibitors of cholesterol biosynthesis, largely used for prevention of cardiovascular diseases induced by hypercholesterolemia. However, their use in different clinical trials clearly indicate that the general benefits observed with statins are also related to effects beyond the cholesterol lowering. Increasing evidences suggest that some of these cholesterol-independent or "pleiotropic" effects of statins involve the interaction and modification of the membrane bilayers. In this manuscript, using a combined approach based on biophysical (electrochemical impedance spectroscopy on tethered bilayer lipid membranes) and biological methods (hemolysis on erythrocytes and immunocytochemistry on cancer cells), we demonstrate that lipophilic, but not hydrophilic statins are capable of reducing the damage caused by cholesterol-dependent cytolysins. This protection correlates with statins lipophilicity and capacity to interact with the lipid bilayer. Our data suggests lipophilic statins associate with membranes and interfere with the ability of cholesterol dependent cytolysins, to bind to membrane cholesterol. Evaluation of the capacity of statins to modulate cell membrane properties is essential for developing a correct therapeutic approach for cardiovascular diseases as well as for understanding the potential of this class of drugs as adjuvants for drug delivery., Competing Interests: Declaration of competing interest The authors declare no competing interests., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF